WithdrawnNot Applicable

Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma

Stopped: Withdrawn due to inability to reach an acceptable agreement with industry sponsor

0Started 2007-01

Plain-language summary

RATIONALE: Glutamine may help prevent mucositis, or mouth sores, in patients receiving chemotherapy for sarcoma. It is not yet known whether glutamine is more effective than a placebo in preventing mucositis in patients receiving chemotherapy for sarcoma. PURPOSE: This randomized clinical trial is studying glutamine to see how well it works compared to a placebo in preventing oral mucositis in patients receiving chemotherapy for sarcoma.

Who can participate

Age range

5 Years – 30 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosed with any of the following: * Ewing's sarcoma * Osteogenic sarcoma * Rhabdomyosarcoma * Other sarcomas (i.e., fibrosarcoma or synovial sarcoma) * Scheduled to receive first course of chemotherapy that includes ≥ 75 mg/m² of anthracyclines * Total modified Walsh score ≤ 2 (mucositis score) PATIENT CHARACTERISTICS: * Must have a caregiver (parent, other relative, or friend) available to perform daily mucositis assessments * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * ALT ≤ 5 times ULN * Albumin ≥ 2 g/dL * No history of hypersensitivity to any known component of AES-14 PRIOR CONCURRENT THERAPY: * No prior glutamine (AES-14) * No prior or concurrent head and/or neck radiation therapy * No concurrent supplementation with another glutamine product * No other concurrent agents for mucositis prophylaxis

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

Trial details

NCT IDNCT00334984

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Childhood Malignant Fibrous Histiocytoma of Bone trials